SCHEMBL2116699

SCHEMBL2116699

COc1ccc(N(Cc2ccccc2)S(=O)(=O)c2ccc(Cl)c(C(=O)O)c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.79
MEN1 O00255 5/20 0.79
LMNA P02545 4/20 0.64
ALDH1A1 P00352 3/20 0.64
PGR P06401 2/20 0.64
NR3C1 P04150 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
CNR1 P21554 1/20 0.57
CNR2 P34972 1/20 0.57
MMP1 P03956 1/20 0.56
MMP9 P14780 1/20 0.56
PTPN1 P18031 1/20 0.56
BCL2L1 Q07817 2/20 0.55
MCL1 Q07820 2/20 0.55
PTPN22 Q9Y2R2 1/20 0.55
PTGES O14684 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2121606 0.89 KMT2A (1.00) KMT2AMEN1LMNAALDH1A1MCL1
SCHEMBL2117091 0.88 KMT2A (1.00) KMT2AMEN1LMNAALDH1A1PGR
SCHEMBL1279470 0.82 PTGES (0.80) KMT2AMEN1LMNAALDH1A1PGR
SCHEMBL1169289 0.82 LMNA (0.68) KMT2AMEN1LMNAALDH1A1PGR
SCHEMBL2119407 0.81 LMNA (0.78) KMT2AMEN1LMNAALDH1A1PGR
SCHEMBL2119250 0.81 MEN1 (1.00) KMT2AMEN1LMNAALDH1A1PGR
SCHEMBL7312470 0.80 MMP9 (0.63) KMT2AMEN1LMNAALDH1A1PGR
SCHEMBL2118123 0.80 MEN1 (1.00) KMT2AMEN1LMNAALDH1A1SMN1; SMN2
SCHEMBL7351229 0.80 MMP9 (0.81) LMNAALDH1A1PGRNR3C1NPSR1
SCHEMBL27569110 0.79 MMP13 (0.70) KMT2AMEN1LMNAALDH1A1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 KMT2A 941/4885MEN1 1593/4885LMNA 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.